843OApalutamide (APA) and overall survival (OS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Updated results from the phase III SPARTAN study - Smith, M R; Saad, F; Chowdhury, S (Ann Oncol, 2019)
et al.